Production & Sales

Camber Pharmaceuticals voluntarily recalls Valsartan tablets in US

Camber Pharmaceuticals is voluntarily recalling all unexpired lots of Valsartan tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level, as a precautionary measure.

Perrigo board approves separation of prescription pharmaceuticals business

Perrigo, a global healthcare company, said that its board of directors approved a plan to separate its Prescription Pharmaceuticals (Rx) business following a previously announced strategic portfolio review.

Abzena completes GMP drug substance manufacture of ABZENA Inside product

Abzena said that it has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanized using the company’s Composite Human Antibody platform.

Sun Pharma launches Kapspargo Sprinkle drug in US

Sun Pharmaceutical Industries has launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure.

LEO Pharma to buy Bayer’s prescription dermatology brands

LEO Pharma, a Danish firm focused on developing drugs for dermatologic and thrombotic patients, has agreed to acquire the global prescription dermatology business of Bayer for an undisclosed price.

Amgen breaks ground on $200m biomanufacturing facility in US

Biopharmaceutical firm Amgen has broken ground on its next-generation biomanufacturing facility in Rhode Island, US.

Pfizer to construct sterile injectable pharmaceutical production plant in Michigan, US

Pfizer has unveiled plans to invest $465m for the development of a new sterile injectable pharmaceutical production facility in Michigan, US.

Abzena signs manufacturing and bioconjugation deal with Telix

UK-based life sciences group Abzena has signed GMP manufacturing and bioconjugation agreements with Australia-based Telix Pharmaceuticals.

Starpharma licenses VivaGel BV to Mundipharma for Europe

Starpharma and Mundipharma have signed a licence agreement for the sales and marketing rights to VivaGel BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America.